Investment banking firm Citigroup (C) Friday came out with mixed results for the second quarter, when earnings rose sharply and came in above analysts’ estimates. Revenues increased modestly, aided by the strength of consumer banking, but missed expectations triggering a stock sell-off.
The banking giant said net income advanced 15% to $4.5 billion during the three-month period. On a per-share basis, earnings jumped 27% to $1.63 per share, exceeding the Wall Street forecast. The bottom line particularly benefitted from a decline in the effective tax rate, which was partially offset by a 6% increase in credit cost.
Driving the profit growth, total revenues moved up 2% annually to $18.47 billion, but missed estimates due to the muted growth rate. Net interest revenue was up 4%. During the quarter, a 20% fall in corporate and other revenues partially offset a 3% cumulative growth in revenues of the Institutional Clients Group and the Global Consumer Banking division, which registered an uptick in all geographical segments.
At the end of the quarter, the bank had $671 billion of loans, up 4% compared to the same period last year. End-of-period deposits rose 4% year-on-year to $997 billion, while book value per share remained broadly unchanged at $71.95.
Revenues increased modestly, aided by the strength of consumer banking, but missed expectations
“Our focus on expenses has given us the ability to self-fund many of our investments and resulted in an improvement in our efficiency ratio for both the second quarter and through the first half of this year,” said Citi CEO Michael Corbat.
Of late, bank stocks have been under pressure from muted yields and softness in lending. While the sector continues to benefit from the recent tax cut and higher interest rates, it is facing headwinds from the ongoing trade war.
Earlier today, Citigroup’s competitor JPMorgan Chase (JPM) reported a 22% growth in second quarter earnings, beating estimates. Among others, Goldman Sachs is scheduled to report its results on July 17.
Citi shares lost nearly 2% in early trading Friday following the earnings report, after closing the last trading session slightly higher. The stock lost more than 7% since the beginning of the year.
Related Infographics: Q1 earnings
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated